login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
XENON PHARMACEUTICALS INC (XENE) Stock News
USA
-
Nasdaq
- NASDAQ:XENE -
CA98420N1050
-
Common Stock
41.88
USD
+0.72 (+1.75%)
Last: 11/24/2025, 2:16:42 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
XENE Latest News, Press Relases and Analysis
All
Press Releases
18 days ago - By: Xenon Pharmaceuticals Inc.
Xenon to Present at Upcoming Investor Conferences
20 days ago - By: Zacks Investment Research
- Mentions:
BEAM
NBIX
FOLD
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
21 days ago - By: Xenon Pharmaceuticals Inc.
Xenon Reports Third Quarter 2025 Financial Results & Business Update
21 days ago - By: Xenon Pharmaceuticals Inc.
Xenon Reports Third Quarter 2025 Financial Results & Business Update
24 days ago - By: Benzinga
Insights into Xenon Pharmaceuticals's Upcoming Earnings
21 days ago - By: Benzinga
- Mentions:
ON
TIMB
GT
IRMD
...
Earnings Scheduled For November 3, 2025
a month ago - By: Xenon Pharmaceuticals Inc.
Xenon to Report Q3 2025 Financial Results on November 3, 2025
a month ago - By: Xenon Pharmaceuticals Inc.
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
a month ago - By: Xenon Pharmaceuticals Inc.
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
2 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
2 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
2 months ago - By: Design Therapeutics, Inc.
- Mentions:
DSGN
CMPS
Design Therapeutics Appoints Justin Gover to Board of Directors
3 months ago - By: Zacks Investment Research
- Mentions:
NTLA
Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?
3 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Zacks Investment Research
- Mentions:
NBIX
CRMD
ALVO
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
3 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Reports Second Quarter 2025 Financial Results & Business Update
3 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Reports Second Quarter 2025 Financial Results & Business Update
4 months ago - By: Xenon Pharmaceuticals Inc.
Xenon to Report Q2 2025 Financial Results on August 11, 2025
4 months ago - By: Xenon Pharmaceuticals Inc.
Xenon to Report Q2 2025 Financial Results on August 11, 2025
4 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Stocktwits
- Mentions:
BIIB
SRPT
ALKS
BHVN
...
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
5 months ago - By: Yahoo Finance
- Mentions:
RY
RY.CA
PNC
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug
5 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Joins the Russell 3000® and Russell 2000® Indexes
5 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Joins the Russell 3000® and Russell 2000® Indexes
5 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
5 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
6 months ago - By: Xenon Pharmaceuticals Inc.
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
6 months ago - By: Xenon Pharmaceuticals Inc.
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
6 months ago - By: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Please enable JavaScript to continue using this application.